NovaBridge Biosciences - Asset Resilience Ratio
NovaBridge Biosciences (NBP) has an Asset Resilience Ratio of 0.08% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NBP net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how NovaBridge Biosciences's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see NovaBridge Biosciences (NBP) total assets.
Liquid Assets Composition Over Time
This chart breaks down NovaBridge Biosciences's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of NovaBridge Biosciences to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.50 Million | 0.08% |
| Total Liquid Assets | $1.50 Million | 0.08% |
Asset Resilience Insights
- Limited Liquidity: NovaBridge Biosciences maintains only 0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
NovaBridge Biosciences Industry Peers by Asset Resilience Ratio
Compare NovaBridge Biosciences's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for NovaBridge Biosciences (2017–2024)
The table below shows the annual Asset Resilience Ratio data for NovaBridge Biosciences.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.43% | $105.14 Million | $212.68 Million | +48.66pp |
| 2023-12-31 | 0.77% | $20.22 Million | $2.61 Billion | -5.01pp |
| 2022-12-31 | 5.78% | $235.43 Million | $4.07 Billion | -7.60pp |
| 2021-12-31 | 13.38% | $753.16 Million | $5.63 Billion | +12.88pp |
| 2020-12-31 | 0.50% | $31.53 Million | $6.33 Billion | -1.34pp |
| 2019-12-31 | 1.84% | $32.00 Million | $1.74 Billion | -8.93pp |
| 2018-12-31 | 10.77% | $255.96 Million | $2.38 Billion | -15.19pp |
| 2017-12-31 | 25.97% | $266.25 Million | $1.03 Billion | -- |
About NovaBridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial fo… Read more